Floyd (“Fred”) D. Loop, MD passed away on June 11, 2015. He was a tremendous pioneer, a sage advisor, and a dear friend.

Dr. Loop was a Medical Advisor to Arch Therapeutics since 2008. He led the Cleveland Clinic as chief executive and was chairman of its Board of Governors from 1989 to 2004, overseeing the center’s growth in size and reputation that made it a world-renowned medical institution. Prior to this, he served as chairman of the clinic’s Department of Thoracic and Cardiovascular Surgery since 1975, five years after joining the Clinic as a cardiac surgeon in 1970. Before ending his surgical career in 1999, he had performed more than 12,000 cardiac surgeries and was the author of 350 papers on all aspects of cardiovascular surgery. He played an important role in the development and refinement of coronary artery bypass graft surgery, improved re-operative techniques, developed innovations in valve repair, and led comprehensive follow-up studies of bypass patients to help establish the world’s first computerized registry of cardiac surgery outcome. His book Leadership and Medicine was published in 1989. Under his leadership, Cleveland Clinic was named one of America’s best hospitals for more than 10 years in a row by U.S. News & World Report.

 As CEO, Loop grew the Clinic to 12 hospitals in Ohio and Florida, 14 family health centers, 2.6 million annual patient visits and $3.5 billion in operating revenue. He launched a philanthropic campaign that enabled construction of the Lerner Research Institute, Cole Eye Institute, Tausing Cancer Center, and the Lerner College of Medicine of Case Western Reserve University. Other facilities founded under his leadership include Cleveland Clinic Innovations and Cleveland Clinic Sports Health. Over three decades as an active surgeon, he was named an honorary member of numerous medical organizations. He served as president of the American Association for Thoracic Surgery in 1997-98.

Dr. Loop earned his BS degree at Purdue University, earned his MD degree at George Washington University, and completed his surgical residency at GWU and with the U.S. Air Force at Andrews AFB.

“Robert (“Bob”) Williams passed away on May 13th, 2020. A brilliant chemist, thoughtful advisor and gifted musician, Bob meant the world to his family and friends

Dr. Williams was an advisor to Arch since 2010. He was a University Distinguished Professor at Colorado State University. Dr. Williams earned his B.A. degree in Chemistry from Syracuse University in 1975 and obtained his Ph.D. degree in 1979 from MIT. He was a post-doctoral fellow at Harvard University (1979-80) prior to joining the faculty at Colorado State University in 1980. He was a visiting Professor at the University of California, Berkeley (1990) and Harvard University (1994-95). Dr. Williams research interests utilized the tools of organic synthesis to study problems in chemical biology and medicinal chemistry. Williams judiciously deployed total synthesis to interrogate hypotheses concerning the biomechanism and/or biosynthesis of complex, biologically significant natural products. Much of Williams’ work on complex alkaloid and peptide synthesis was based on his development of a practical and commercialized technology for the asymmetric synthesis of a-amino acids, peptide isosteres, peptides and depsipeptides. Dr. Williams received several Honors and Awards including the NIH Research Career Development Award, The Eli Lilly Young Investigator Award, Fellow of the Alfred P. Sloan Foundation, the Merck, Academic Development Award, the Japanese Society for the Promotion of Science Fellowship, the ACS Arthur C. Cope Scholar Award and the ACS Ernest Guenther Award in the Chemistry of Natural Products. He served on the Editorial Board of Chemistry & Biology; as Editor for the journal Amino Acids (1991~1998) and was a Series co-Editor for The Organic Chemistry Series, (Elsevier). Dr. Williams was a Founding Scientist for several biopharmaceutical companies including Microcide Pharmaceuticals, Xcyte Therapies, HemaQuest Therapeutics, Cetya Therapeutics and Sapientia Therapeutics.